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ABSTRACT 
     Adult mammalian hearts lack self-renewal and proliferative capabilities 
necessary for cardiovascular regeneration. Current treatments using cardiac 
progenitor cells (CPCs) for cell-based repair do not restore cardiac function in 
patients who experience a myocardial infarction (MI). Our laboratory has been 
studying Islet-1+ neonatal CPCs as a promising candidate for cell-based repair 
due to their ability to significantly improve cardiac function after MI in sheep. The 
current study addresses the hypothesis that the ERBB pathway is linked to the 
Hippo-pathway to activate YAP1 by the involvement of an autocrine loop that 
upregulates neuregulin (NRG). In our sheep model of MI and cardiovascular 
progenitor cell-based  repair, tissue sections from  the infarct zone of three 
neonatal Islet-1+ CPC treated sheep and corresponding control cardiac tissue 
sections were used to extract RNA, prepare cDNA and perform RT-qPCR to 
quantify transcripts associated with the NRG-ERBB signaling pathway. Induced 
levels of NRG1 and NRG2 were identified in the cardiovascular repair zone of 
Islet-1+ CPC treated infarcted sheep. ERBB receptors 1-4 and PIK3C2B levels 
were induced following cell-based treatment.  In addition, RT-qPCR and western 
blot experiments were done on human neonatal Islet-1+ CPCs treated with and 
without Wnt5a to investigate transcripts associated with the ERBB pathway and 
YAP1 protein expression. We showed an increase in the expression of NRG1, 
IV 
ERBB3, PIK3CD, and YAP1 after 72 hrs of Wnt5a treatment along with 
overexpression of YAP1 protein at 144 hrs following Wnt5a treatment. Our 
studies provide new insight into the mechanism by which ERBB signaling 
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Stem Cell Populations Used as Therapeutic Treatment for Myocardial Infarction 
Myocardial Infarction (MI) can result in the formation of scar tissue leading 
to cellular injury or death. Left ventricular dilatation is a precursor of ventricular 
dysfunction and congestive heart failure (CHF) after MI (Yeboah, 2014). Left 
ventricle damage after MI undergoes progressive remodeling and the heart wall 
muscle becomes permanently impaired. Adult hearts are incapable of 
regenerating lost cardiac cells and cannot repair scar tissue. With this in mind, 
stem cell- based therapies are becoming important treatments in the area of 
heart disease. There are many stem cell candidates that are being tested in 
cardiac regenerative therapy. Bone marrow mononuclear cells (BMNCs) were 
the first hematopoietic cells to have been used in cardiac therapy (reviewed in 
Behfar, 2014). In some cardiac repair clinical trials, BMNCs contributed to 
angiogenesis, neovascularization, improved cardiac function, and increase in left 
ventricular ejection fraction (LVEF) (Ashara, 1999; Fujii, 2004; Liu, 2014). 
However, other studies reported that intracoronary infusion of BMNCs did not 
promote functional myocardium (de Jong, 2014; Lunde 2006). Other types of 




Mesenchymal stem cells (MSCs) are derived from bone marrow stem cells 
that have plastic adherence characteristics and are capable of expressing 
CD105, CD73, and CD90 but not CD34, CD45, CD14 or CD11b, CD79α or 
CD19, and HLA-DR (Dominici, 2006). In vitro, MSCs have the potential to form 
adipocytes, chondrocytes, and osteoblasts (Dominici, 2006). MSCs are, 
however, beneficial for cardiac repair due to their release of cytoprotective 
molecules (reviewed in Genecchi, 2008). These molecules contain 
cardioprotective effects and stimulants that activate repair in the MI heart 
(Hatzistergos, 2010). In clinical trials, therapeutic efficiency of MSCs, when 
transplanted along with autologous or allogeneic cell sources showed promising 
signs of reduced scar mass and improved cardiac function in heart failure 
patients (Hare, 2012). MSCs have benefits, but they do have some 
disadvantages in the therapeutic setting, including the inability to differentiate into 
functional cardiomyocytes (CMs) (Rose, 2008). 
 C-kit+ cells represent a population of cells that was the focus of attention in the 
cardiac repair field for many years (Gude, 2018). Recently, however, the 
capability of some of these c-kit+ cells to differentiate into CMs in vivo has 
become controversial. The use of c-kit+ cells to repair the adult mouse heart after 
MI was based on an early study. Mice with infarcted hearts that were treated with 
cells isolated from sorted, bone marrow derived lineage Lin− and c-kit+ cells that 
were tagged with enhanced green fluorescent protein (eGFP) showed 




encompassed 68% of the infarcted region after transplantation (Orlic, 2001). 
However, other research labs failed to reproduce differentiation of these cells into 
CMs in adult mice (Jesty, 2012; Murry, 2004). In a phase 1 clinical trial called 
SCIPIO, c-kit+ cells were reported to promote cardiac regeneration (reviewed in 
Mauretti, 2017), but the study was later retracted due to issues with the data. 
Next, cardiospheres have also been studied in models of cardiovascular repair. 
Cardiospheres contain mixed cell populations; cardiac stem cells (c-kit+, etc.), 
endothelial precursors, and mesenchymal cells (Messina, 2004). Cardiosphere-
derived cells (CDCs) have been used in vivo in animal models (Chimenti, 2010; 
Johnston, 2009) and in human clinical trials (Makkar, 2012; Makkar, 2020). In MI 
animal models, CDC administration reduced infarct size, improved LVEF, and 
improved cardiac hemodynamics in vivo (Chimenti, 2010; Johnston, 2009). In 
human studies, cardiosphere-derived autologous stem cells were shown to be 
safe, but exhibited no reduction of scar size in the infarct zone (Makkar, 2020). 
 Due to the need to identify a potentially beneficial cell type with the ability to 
differentiate into functional CMs, induced pluripotent stem cells (iPSCs) gained 
increasing attention. iPSCs can differentiate into CMs similar to embryonic stem 
cell (ESC) derived CMs (Pfannkuche, 2009). In MI mice, iPSC injection resulted 
in differentiation of CMs, improved cardiac function and increased ventricular wall 
thickness (Nelson, 2009). Other studies show that after iPSC transplantation, 
there was no evidence of increased T-cell proliferation or antigen specific 




iPSCs (Guha, 2013). There are some risks associated with iPSCs, however. 
Teratoma formation can occur when the genetic material in iPSCs randomly 
integrates in the host genome (Li, 2011).Various sources of iPSCs can contribute 
to differences in genotype, phenotype, and the epigenome (reviewed in Liang, 
2013). The use of iPSCs can be complex due to variable factors. Small 
molecules may be needed to enhance iPSC production without the use of viral 
vectors for gene modification (Li, 2011). Using iPSCs in cardiac therapy can lead 
to variable results in engraftment rate and risk of arrhythmia (reviewed in 
Hashimoto, 2018). Despite these issues, generation of mature iPSC- derived 
CMs has been improved and the cells can be produced with greater purity 
(Hashimoto, 2018). Hydrogels and cell sheets used as scaffolds for iPSC-derived 
CMs have been used in the therapeutic setting for treating diseases (Chow, 
2017). Overall, these cells remain a promising approach for heart repair after 
injury. 
Islet-1+ Cardiac Progenitor Cells 
Islet-1 is a transcription factor that plays a role in regulating heart 
development during embryogenesis. This marker is expressed in multipotent 
cardiac progenitor cells (CPCs) that can differentiate into all three cardiac cell 
types (cardiomyocytes, smooth muscle cells, and endothelial cells) (Moretti, 
2006). Islet-1+ is necessary for heart development and is the specific marker for 
development of the SHF, which generates cells to form the large portions of the 




was found to be expressed in the7.5 day old mouse throughout the anterior intra-
embryonic coelomic walls and proximal head mesenchyme, regions found in the 
FHF and SHF (reviewed in Laugwitz, 2008; Prall, 2007). Studies have 
determined Islet-1+ as a marker of CPCs (Bartulos, 2016; Domian, 2009). In 
rodents, Islet-1+ CPCs administered to infarcted hearts showed improvement of 
left ventricular function, enhanced vascularization, reduced myocardial 
dysfunction, and enhanced CM proliferation (Bartulos, 2016; Barzelay, 2012). 
Islet-1+ CPCs are the main focus of research in our lab because they are self-
renewing, clonogenic, and multipotent (Baio, 2017). We have shown that Islet-1+ 
neonatal CPC transplantation in MI sheep improves overall cardiac function 
(Hasaniya, 2018) and that Islet-1+ CPCs maintained on a hyper-cross linked 
polymer scaffold promote proliferation and differentiation (Baio, 2017). Other 
studies showed improvement of cardiac function in MI mice after Islet-1+ CPC 
transplantation in SIS-ECM and gelatin microsphere scaffolds (Feyen, 2016; 
Wang, 2017). Islet-1+ human embryonic stem cells (hESC) promote an increase 
in CM differentiation rather than stabilizing the cardiac precursor cell state 
(Quaranta, 2018). Our lab demonstrated proliferation and differentiation of Islet-
1+ CPCs in vivo into CMs and endothelial cells at the site of repair following MI in 
a sheep model (Hasaniya, 2018). The mechanistic basis for efficient 
cardiovascular regeneration in this model is currently under investigation.  
Several signaling pathways appear to be activated following Islet-1+ cell 




Hippo- YAP1 Role in Cardiac Regeneration 
YAP1 is an important regulator in promoting cell proliferation, survival, and 
growth during cardiac development and repair (Gumbiner, 2014). Activation of 
the Hippo signaling pathway stimulates MST1/2 kinases along with the binding of 
SAV1 and PDK1. This complex promotes activation of LATS1/2 kinases, which 
results in phosphorylation of YAP1 (Fig. 1). As a result, phosphorylated YAP1 is 
prevented from entering the nucleus, which leads to apoptosis (Gumbiner, 2014). 
On the flip side, inactivated Hippo pathway promotes accumulation of 
dephosphorylated intranuclear YAP1, which allows it to interact with other 
transcription factors (TEAD1-4) that regulate cell growth, survival, and 
proliferation (Fig. 1) (Gumbiner, 2014). Studies in mice have shown that deletion 
of the upstream kinases MST1/2 and LATS1/2 induces CM proliferation during 
mouse embryogenesis (Heallen, 2011; Heallen, 2013). In MI mice, cardiac 
deletion of YAP1 significantly impairs cardiac regeneration, but overexpression of 
a constitutively active form of YAP1 reduces scar size, increases CM proliferation 
and improves cardiac function (Xin, 2013). In our lab, we showed increased 
expression of YAP1 in a sheep model of myocardial infarction following 
transplantation of neonatal sheep Islet-1+ CPCs when compared to controls 
(Camberos, 2019). In addition, high levels of YAP1 are expressed in human 
neonatal Islet-1+ CPCs, but declines to insignificant levels inadultIslet-1+ CPCs 
(Camberos, 2019). This is a contributing factor in human neonatal Islet-1+ CPC 




cells from apoptosis and is sufficient for induction of cardiac regeneration after 
heart injury (Xin, 2013). 
 
 
Figure 1: Hippo-YAP1 Signaling Pathway  
YAP1 is phosphorylated by LATS1/2, which prevents YAP1 from entering the 
nucleus when the Hippo pathway becomes active (on). Ligand binding to 
receptor tyrosine kinase (RTK) inactivates (off) the Hippo pathway, thereby 
promoting dephosphorylation of YAP1 to enter the nucleus and interact with 








ERBB Signaling Pathway 
It is now understood that signaling pathways stimulating cardiovascular 
repair activate proliferation and dedifferentiation (reviewed in Xin, 2013). In 
humans, CM regeneration also involves the signaling pathways of ERBB family 
proteins. This family contains four receptor tyrosine kinases (RTKs), which 
include ERBB1, ERBB2, ERBB3, and ERBB4. These receptors interact with 
neuregulins (NRGs), which are epidermal growth factor ligands. NRGs are 
homologous proteins that are encoded by genes NRG1, NRG2, NRG3, and 
NRG4. In mammalian cells, NRGs bind and activate ERBBs, which triggers a 
network of signaling pathways that promotes proliferation, dedifferentiation, cell 
migration, and survival (reviewed in Xu, 2010). More specifically, NRG1 activates 
ERBB3 and ERBB4 both of which form heterodimers with the ERBB2 receptor to 
further activate multiple signaling pathways (reviewed in Citri, 2006). ERBB2 
lacks binding sites for growth factor ligands (including NRGs), so ERBB2 
requires heterodimerization with other ERBB family receptors to function (Citri, 
2006). ERBB3 activates the PI3K pathway by interaction with ERBB2 (Song, 
2015). PI3K activity initiates signaling cascades that impact AKT (reviewed in 
Jean, 2014). AKT controls multiple pathways (including activation of FOXO, 
mTORC1, and YAP1) to regulate cell proliferation, growth, metabolism, survival, 
and autophagy (reviewed in Vanhaesebroeck, 2012). ERBB2 is important in 




MI trauma (D’Uva, 2015) and triggers epithelial mesenchymal transition (EMT) 
during regeneration of cardiac tissue (Aharonov, 2020).   
NRG-1 has been evaluated as a therapeutic option in treating 
acute/chronic heart disease in pre-clinical rodent models. Recombinant human 
NRG-1 (hrNRG-1) was used to pretreat rodents prior to MI by left anterior 
descending coronary artery ligation (LAD) and this treatment reduced ventricular 
arrhythmia (VA) and improved overall cardiac function in the heart (Gu, 2010; 
Rao, 2019). In addition, hrNRG-1 has been administered intravenously in chronic 
heart failure (CHF) in patients with LVEF < 40 % in a phase II, randomized, 
double-blind trial (Gao, 2010). In this trial, rhNRG-1 treatment improved LVEF by 
31.99 % when compared to a 15.05% increase in patients treated with the 
placebo for three months (Gao, 2010). Short term treatment with rhNRG-1 was 
shown to have long term effects in reversing adverse cardiac function (Gao, 
2010). Currently, there are hrNRG-1 clinical trials that are actively recruiting 
patients with CHF to better understand the underlying mechanisms by which 
damaged CMs can be repaired and function restored (reviewed in De Keulenaer, 
2019). Surprisingly, there is limited literature addressing NRG2 and whether or 
not it can impact cardiac regeneration through interactions with ERBB receptors. 
NRG2 mRNA has been found in the endothelial lining of the heart in adult rats 
(Carraway Iii, 1997). The highest NRG2 levels were found in the atrium, the 
lower levels of the ventricle, and in the outflow tract (Carraway lii, 1997). NRG2 




which Neuregulins, ERBB and YAP1 signaling pathway interact to facilitate 
cardiac repair have not been elucidated. 
In summary, transplantation of Islet-1+ CPCs in MI sheep has been shown 
to stimulate CM proliferation and improve overall cardiac function but the 
signaling pathways that play a role in this process have not been fully elucidated. 
Understanding the molecular events that lead to cardiac repair following neonatal 
cardiovascular stem cell transplantation may lead to further improvements in cell-
based cardiac therapy. Specifically, the Hippo-Yap1 pathway plays a key role in 
cardiac repair but the regulatory pathways that activate YAP1 are still under 
investigation. ERBB activation by NRG relays signals downstream to the PI3K 
pathway and this signaling may subsequently activate the Hippo-Yap1 pathway 
to promote cell survival, differentiation, and proliferation of CMs. The current 
study will address the hypothesis that the ERBB pathway activates YAP1 by the 
involvement of an autocrine loop that upregulates NRG (Fig. 2). This concept will 
be studied in a sheep model of myocardial infarction and cardiovascular 







Figure 2: ERBB/ YAP1/ NRG Signaling Forms an Autocrine Loop 
This diagram shows NRG binding to the ERBB3/ERBB2 receptor tyrosine 
kinases (RTKs), which stimulates downstream signaling to the PI3K-AKT 
pathway to promote cell survival. In addition, activation of PDK1 indirectly inhibits 
the Hippo Kinase Cascade (Fan, 2013), which activates YAP1 by 
dephosphorylation, allowing YAP1 to pass through the nucleus to interact with 
transcription factors (TFs) on the DNA strand (Gumbiner, 2014). YAP1 stimulates 
gene expression to induce cell growth and proliferation with indirect positive 
regulation from AKT (Fan, 2013). The autocrine loop interaction may occur when 
the expression of intranuclear YAP1 is elevated, resulting in the upregulation of 
NRG downstream of YAP1. NRG is transported through the cell membrane to 






Definition of Terms 
CHF: Congestive heart failure. MI: Myocardial infarction. CPCs: 
Cardiovascular progenitor cells. CSCs: Cardiac stem cells. iPSCs: Induced 
pluripotent stem cells. MSCs: Human mesenchymal stem cells. CDCs: 
Cardiosphere derived cells. BMNCs: Bone marrow mononuclear cells. HSCs: 
Hematopoietic stem cells.  HESCs: Human embryonic stem cells. EPDCs: 
Epicardial-derived cells. HUVECS: Human umbilical vein endothelial cells. NRG: 
Neuregulin. CMs: Cardiomyocytes. LECs: Lymphatic endothelial cells. EF: 
Ejection fraction. LVEF: Left ventricular ejection fraction. EMT: Epithelial 
mesenchymal transition. ECM: Extra-cellular matrix. RTKs: Receptor tyrosine 
kinases. RT-qPCR: Reverse transcription quantitative PCR.  GPCRs: GTP-















MATERIALS AND METHODS 
 
Sheep Model of Myocardial Infarction 
Sheep (<1 year old) were previously infarcted via left anterior descending 
coronary artery ligation. After three to four weeks following infarction, sheep were 
injected with 10 million sheep neonatal cardiac progenitor cells. The sheep were 
euthanized after two months of cell injection and their hearts were collected. 
Sheep hearts were mapped and sections were taken according to their proximity 
to the infarct site. Tissue samples from neonatal sheep (n=5) were flash frozen 
for experimental use. The animal studies were approved by the Institutional 
Animal Care and Use Committee of Loma Linda University and performed within 
the regulations of the Animal Welfare Act. Tissue samples from normal sheep, 
non-infarcted sheep, infarct-only sheep and sheep which were previously 
infarcted and treated with Islet-1+ cells for cardiac repair were used for RNA 
isolation and purification. 
Islet-1+ Cardiac Progenitor Cell Isolation and Clonogenic Culture  
Human and Sheep cardiac progenitor cell clones have been previously 
isolated as described by Fuentes and Hou, respectively (Fuentes, 2013; Hou, 
2012). Human cardiac progenitor cell clones were cultured and grown on 0.1% 




containing 10% fetal bovine serum (Thermo Scientific, Waltham, MA), 100 µg/mL 
penicillin–streptomycin (Life Technologies, Carlsbad, CA), and 1% minimum 
essential medium non-essential amino acids (Life Technologies, Carlsbad, CA). 
The Institutional Review Board at Loma Linda University approved the protocol 
for using discarded human cardiovascular tissue obtained after cardiac surgery 
without the use of identifiable patient information, following a waiver of informed 
consent.  
 
Treatment of Human Neonatal Islet-1+ Cardiac Progenitor Cells with Wnt5a  
Wnt5a treatment has been shown to induce intranuclear YAP1 expression 
(Park, 2015). High levels of YAP1 in the nucleus may result in an increased 
expression of NRG, which binds and activates ERBB signaling pathway in an 
autocrine effect. In order to demonstrate this, human neonatal Islet-1+ CPC 
clones were grown to 60-70% confluency and were treated with 100 ng/ml of 
recombinant human/mouse Wnt5a (R&D Systems, Minneapolis, MN) in CPC 
growth media as previously described by (Baio,2018). Islet-1+ CPCs were 
cultured with Wnt5a for 48 hrs, 72 hrs, and 96 hrs time periods in order to induce 
YAP1 expression. Untreated CPCs were grown in normal CPC growth media for 
use as a control. At each corresponding time period of Wnt5a treatment, treated 
and control Islet-1+ CPCs were washed with phosphate buffered saline followed 




from treated and untreated Islet-1+ CPCs for western blot analysis at the 96 and 
144 hour timepoints. 
RNA Purification and RT-qPCR 
Purification of total RNA from sheep and Wnt5a treated human neonatal 
Islet-1+CPC samples was performed by using an RNeasy mini kit (Qiagen, 
Valencia, CA, USA) following the manufacturer's instructions. The integrity of the 
RNA was validated using gel electrophoresis prior to preparing cDNA for each 
sample. 2 µg of RNA was used to prepare cDNA using Superscript III (Invitrogen, 
Carlsbad, CA). RT-qPCR was performed with a Bio-Rad CFX96 Touch Real-
Time PCR Detection System (Bio-Rad, Hercules, CA, USA). PCR plates were 
run under the following conditions: 94 °C for 10 min, 94 °C for 15 s, 58 °C for 1 
min, 72 °C for 30 s, repeated for 40 cycles. The primers for our genes of interest 
were developed by NCBI Primer-BLAST (Table 1). RT-qPCR products were 
visualized using 1%-2% agarose gel electrophoresis and low mass DNA ladder 
(Invitrogen, Carlsbad, CA). 
Western Blot and Protein Purification of Human Neonatal Islet-1+ Cardiac 
Progenitor Cells after Wnt5a Treatment 
Human neonatal Islet-1+ CPCs treated with Wnt5a at 96 hr and 144 hr 
time periods were each washed with cold phosphate buffer saline and treated 
with cold trypsin. Trypsinized cells were placed on ice at room temperature until 
all cells rose. These two samples (96hr and 144hr) were each collected and 




EDTA, protease inhibitor cocktail, sodium orthovanadate, and sodium fluoride, 
before being centrifuged at 14,000× g, and aliquoted for use. Protein 
concentrations at each Wnt5a treated time point were quantified using the Micro 
BCA Protein Assay Kit (ThermoFisher, Waltham, MA, USA). Protein Simple Wes 
(Protein Simple, San Jose, CA, USA) was used to analyze protein levels 
according to the manufacturer’s protocol. Antibodies used in western blot (Table 




Data was analyzed using PRISM and was reported as mean +/- standard 
error.  P values <.05 were deemed significant. Triplicate qPCR replicates were 
used for RT-qPCR experiments. GAPDH and actin were used as normalizing 
genes in these experiments. Data was calculated using the ∆∆ CT method 
(Livak, 2001) 
 
Table 1: Primer Pairs Used in RT-qPCR 
Human Genes Forward Sequence Reverse Sequence 
NRG1 GAA AAG AAA TCC TGT 
GTG TCG CT 
TGG CAG GTG ATC ACT 
GGG ATA 
NRG2 CGA GAA GAG CCA CTC 
GAC AG 
ACA TTT CAG GAC AGG 
ATT CCC A 
ERBB1 ACT TCT ACC GTG CCC 
TGA TG 
TGT CTG CAA ATC TGC 
CAC TGT 
ERBB2 CAT TGG GAC CGG AGA 
AAC CAG 





ERBB3 TGA GAT TGT GCT CAC 
GGG AC 
ATC TCG GTC CCT CAC 
GAT GT 
ERBB4 TTC AGG ATG TGG ACG 
TTG CC 
GGG CAA ATG TCA GTG 
CAA GG 
PIK3C2B GGC CAT CAC TTC CCT 
GAG AAA 
GCT AAG GCT TCC TTC 
AGC CA 
PIK3CD CTG CGC CGG GAC GAT GGA AGA GCG GCT CAT 
GG 
YAP1 TCC CAG ATG AAC GTC 
ACA GC 
TCA TGG CAA AAC GAG 
GGT CA 
Sheep Genes   
NRG1 TGG TGA TCG CTG CCA 
AAA CT 
CAG CTG TGA CTG GGA 
GTC TG 
NRG2 GGT AAC CCT CTG CCC 
TCC TA 
CAT TGC GAA CTG CTG 
ACA CC 
ERBB1 GAC TTT ACT GGG GCC 
TGA CC 
ACG TGT TAC CTG GAA 
GGC TG 
ERBB2 AGA TCC TCA AGG GAG 
GGG TC 
GAA GGT ATA ACG CCC 
CTC GG 
ERRB3 AGT GCC TAT CTT GCC 
GGA AC 
CTT GTA GAT GGG GCC 
CTT GG 
ERBB4 AGT CAC AGG CTA CGT 
GTT GG 
CAG GTT GGA AGG CCA 
TGG AT 
PIK3C2B CGC AGG TGC CCA GAC 
A 
GTA GAG TGG TTG GAC 
AGC CC 
PIK3CD AAC CCC AAC ACT GAG 
AGT GC 
CTC GGA GGT TAG TTT 
CCG CA 
 















































Islet-1+ Progenitor Cell-Treated Sheep 
NRG1 and NRG2 Transcripts are Induced in Islet-1+ Progenitor Cell-Treated 
Sheep 
In order to assess the role of ERBB signaling in cardiovascular repair, 
RNA was isolated from sheep tissues preserved from the cardiovascular infarct 
zone. cDNA was synthesized and RT-qPCR was performed to assess levels of 
NRGs that may be induced after myocardial injury alone and during 
cardiovascular regeneration after neonatal sheep Islet-1+ CPC treatment. 
Myocardial infarcted sheep treated with neonatal sheep Islet-1+ CPCs in the 
infarct zone and normal control age- matched sheep were compared. The normal 
control aged-matched sheep is a healthy sheep with no infarction and without cell 
treatment.  NRG1 and NRG2 gene expression analysis by RT-qPCR 
demonstrated that both NRG1 and NRG2 gene levels were significantly 
elevated in the cardiovascular repair zone of Islet-1+ CPC treated infarct sheep 
when compared to normal control aged- matched sheep (Fig. 3A, 61.9 + 3.64 
fold change, **** p<.0001. Fig. 3B, 24.1 + 1.9 fold change, *** p=.0003, 
respectively). NRG1 was more highly expressed in Islet-1+ cell treated sheep 




addition, NRG1 and NRG2 gene expression levels were both elevated in the 
cardiovascular repair zone of Islet-1+ cell treated sheep when compared to the 
non-infarct region in Islet-1+ cell treated infarcted sheep by RT-qPCR analysis 
(Fig. 3C, 3.7 + 0.96-fold change, ns. P=0.1028. Fig. 3D, 5.4+ 0.18-fold change, 
**P=0.0017). Next, NRG1 and NRG2 gene expression in the infarct region 
of myocardial infarcted sheep with no cell treatment was compared to normal 
control aged-matched sheep by RT-qPCR. NRG1 and NRG2 gene transcripts 
were both downregulated in infarct only sheep when compared to normal control 
age-matched sheep (Fig. 4A, .43 + .01-fold change, ns. Fig. 4B, .125  + .03-fold 




       
     
Figure 3: NRG1 and NRG2 Transcripts are Elevated in Infarcted, Islet-1+ 
Cell Treated Sheep  
NRG1 (A) and NRG2 (B) gene transcripts were elevated in Islet-1+ cell treated 
infarcted sheep (Infarct + Cells) when compared to normal control age-matched 
sheep (Control) as shown by RT-qPCR. NRG1 (C) and NRG2 (D) gene 
transcripts were also elevated in Islet-1+ cell-treated infarcted sheep (Infarct + 
Cells) when compared to the non-infarct region in Islet-1+ cell treated infarcted 




SEM (standard error of the mean). All samples were run in triplicates and were 
normalized to GAPDH. Data was calculated using ∆∆ CT. 
 
 
Figure 4: NRG1 and NRG2 Transcripts are Downregulated in the Absence 
of Cell Treatment in Infarcted Sheep 
NRG1 (A) and NRG2 (B) gene transcripts were downregulated in the infarct 
region of sheep in the absence of cell treatment when compared to normal 
control age-matched sheep (control) as shown by RT-qPCR. Fold changes are 
shown as the mean + SEM. All samples were run in triplicates and were 
normalized to GAPDH. Data was calculated using ∆∆ CT. 
 
ERBB Receptor Expression is Elevated in the Cardiovascular Repair Zone 
following Islet-1+ Progenitor Cell Treatment in Infarcted Sheep 
ERBB expression levels in the cardiovascular repair zone of three Islet-1+ 
progenitor cell-treated sheep were compared to ERBB levels in their respective 
non- infarct regions. Gene expression levels identified by RT-qPCR are shown as 
an average of three sheep per group in Figure 5. ERBB1 (3.62 + .48 fold change, 
****P<.0001), ERBB2 (2.37 + .52 fold change, * P=.0172), ERBB3 (5.87 + 1.74 
fold change, *P=.0127), ERBB4 (2.24 + .44 fold change, ****P=.0123), and 




sheep samples treated with Islet-1+ progenitor cells (Fig. 5). ERBB3 transcripts 
were most highly expressed in response to cell treatment in myocardial infarcted 
sheep. Activation of this receptor stimulates expression of PIK3C2B (class 2 
PI3K), thereby triggering YAP1 expression downstream (Camberos, 2019) to 








Figure 5: ERBB 1-4 Transcripts are Elevated in Infarcted, Islet-1+ Cell 
Treated Sheep 
By using RT-qPCR, ERBB1, ERBB2, ERBB3, ERBB4, and PIK3C2B transcripts 
were all significantly elevated following neonatal sheep Islet-1+ CPC 
transplantation in sheep post-infarction (Infarct + Cells) when compared to the 
non- infarct region (Control). Fold changes are shown as the mean + SEM. All 
samples were run in triplicate and were normalized to GAPDH. Data was 




Islet-1+ Progenitor Cell-Treated Sheep Summary 
In summary, we showed elevated transcripts encoding NRG1, NRG2, 




infarcted sheep. Cell-based treatment induces NRG1 and NRG2 which bind and 
activate the ERBB3 signaling pathway, resulting in downstream activation of the 
PIK3C2B (class 2 PI3K) pathway. Our lab has previously shown induced 
expression of YAP1 in Islet-1+ cell treated neonatal sheep (Camberos, 2019). 
With this in mind, PIK3C2B activation turns off the Hippo pathway and promotes 
YAP1 expression in the nucleus where it can upregulate NRG1 and NRG2 to 
rebind with ERBB3 receptors in an autocrine loop effect (Fig. 2). These findings 
led us to investigate whether the autocrine loop concept is activated within the 
ERBB signaling pathway in our human neonatal Islet-1+ CPCs in vitro. 
 
Human Neonatal Islet-1+ Cardiac Progenitor Cells 
Activation of YAP1 Induces NRG and Activates ERBB Signaling in Human 
Neonatal Islet-1+ CPCs in Vitro 
We treated human neonatal Islet-1+ CPCs with Wnt5a to determine 
whether activation of YAP1 promotes upregulation of NRG and subsequently 
elevates ERBB expression as an autocrine loop. Studies have shown that cells 
treated with Wnt5a promotes expression of YAP1 (Park, 2015). Human neonatal 
Islet-1+ CPCs were therefore treated with Wnt5a in our study for 48 hrs, 72 hrs, 
96 hrs, and 144 hrs. RNA was extracted from these cells at 48 hrs and 72 hrs for 
RT-qPCR analysis. In addition, protein was extracted from a separate sample of 
cells at 96 hrs and 144 hrs for Western blot analysis. The cells were treated with 




timepoint. The Wnt5a was removed to allow assessment of the potential for 
YAP1 activation in the cells to continue to be induced in the absence of Wnt5a 
and as a consequence of amplification via an autocrine loop. These experiments 
were designed to determine whether activation of YAP1 results in 
dephosphorylation of YAP1, translocation to the nucleus and elevated expression 
of NRG, which subsequently activates the ERBB signaling pathway (Fig. 2).  
Activation of ERBB signaling then continues to maintain YAP1 expression at high 
levels by signaling through PI3K-AKT pathways. 
Activation of YAP1 in Human Neonatal Islet-1+ CPCs Results in Elevated 
Expression of NRG1 and ERBB3 
Human neonatal Islet-1+ CPCs were treated with 100 ng/ml of 
recombinant human/mouse Wnt5a in CPC growth media for 48hrs and 72 hrs. 
After 48 hrs of Wnt5a treatment, NRGs, ERBBs, PI3Ks, and YAP1 gene 
expression levels were evaluated by RT-qPCR (Fig. 6). NRG1 gene 
expression in Wnt5a treated human neonatal Islet-1+ CPCs was significantly 
elevated when compared to NRG1 gene expression levels in the untreated 
control group (2.49 +. 097-fold change, ** P=.0048). In addition, ERBB3 
transcript levels were significantly induced in treated CPCs when compared to 
the control group (2.36 + .26-fold change, * p=.0337). There was also an 
increasing trend towards elevated transcripts encoding NRG2 (Fig. 6B), ERBB2 
(Fig. 6G), and PIK3CD (Fig. 6D). No difference in gene expression was identified 




towards downregulation of gene expression for ERBB1 (Fig. 6F) and ERBB4 
(Fig. 6I) in treated vs. control groups. 
Next, NRGs, ERBBs, PI3Ks, and YAP1 gene transcripts after 72 hrs of 
Wnt5a treatment were analyzed by RT-qPCR (Fig. 7). NRG1 gene 
expression was significantly elevated in treated human neonatal Islet-1+ CPCs 
when compared to the untreated control group (3.49 + .097-fold change, ** 
P=.0048). ERBB3 gene expression was also significantly upregulated in the 
treated group (3.5+ .37-fold change, * P=.012). PIK3CD gene expression was 
significantly elevated after treatment (12.5 + .26-fold change, *** p=.0337) and 
YAP1 gene transcripts were significantly induced (2.12 + .065-fold change, ** 
p=.0034). Next, there was a slight increase in transcripts encoding NRG2 (Fig. 
7B) in treated cells. PIK3C2B (Fig. 7C), ERBB1 (Fig. 7F), ERBB2 (Fig. 7G), and 
ERBB4 (Fig.7I) gene expression levels were all downregulated in Islet-1+ CPCs 
treated with Wnt5a when compared to the control group. After 72 hrs of Wnt5a 
treatment, NRG1 was upregulated and may therefore have the potential to bind 
and activate the ERBB3 receptor tyrosine kinase, thereby inducing PIK3CD 
(class 1 PI3K) expression downstream. This activation of PIK3CD may further 
increase expression of YAP1, which then may promote upregulation of NRG1 






Figure 6: NRG1 and ERBB3 Transcripts are Elevated after 48 hrs of Wnt5a 
Treatment in Human Neonatal Islet-1+ CPCs  
RT-qPCR analysis revealed that NRG1 (A) and ERBB3 (H) gene transcripts were 
significantly elevated in Wnt5a treated human neonatal Islet-1+ CPCs at 48 hrs 
(treated) when compared to the untreated control group. Fold changes are 
shown as the mean + SEM. All samples were run in triplicates and were 







Figure 7: Activation of YAP1 after 72 hrs of Wnt5a Treatment in Human 
Neonatal Islet-1+ CPCs Results in Elevated Expression of NRG1 and 
ERBB3 
RT-qPCR analysis revealed that NRG1 (A), ERBB3 (H) PIK3CD (D), and YAP1 
(E) transcripts were all significantly elevated in Wnt5a treated human neonatal 
Islet-1+ CPCs at 72 hrs (treated) when compared to untreated control group. 
Fold changes are shown as the mean + SEM. All samples were run in triplicates 
and were normalized to actin. Data was calculated using ∆∆ CT. 
 
YAP1 Protein Expression is Elevated in Human Neonatal Islet-1+ Cardiac 
Progenitor Cells Treated with Wnt5a at 96 hrs and 144 hrs 
Protein Simple Wes is an automated gel free Western blot device that is 
capable of performing multiple protein assays in their respective lanes as well as 




recombinant human/mouse Wnt5a in CPC growth media was used to activate 
human neonatal Islet-1+ CPCs. YAP1 protein and phosphorylation levels were 
assessed at 96 hrs and 144 hrs by Western blot (Fig. 8A) after removal of Wnt5a 
from the cell culture. These cells were grown without Wnt5a stimulant for 3 days 
(144 hrs total). As a result, there was a gradual increase in YAP1 expression 
from 96 hrs (Fig. 8B. 1.41 + .02-fold change, ***P<.0001) to 144 hrs (Fig. 8B. 
2.55 + .14-fold change, **P<.0001) when compared to the control, respectively. 
In addition, YAP1 expression was significantly induced in the 144hr Wnt5a 
treated group (Fig. 8B. 2.55 + .25-fold change, **P<.001) when compared to the 
96 hr Wnt5a treated group. CPCs examined at 144 hrs showed an increase in 
YAP1 protein expression levels after removal of Wnt5a when compared to earlier 
timepoints (Fig. 8B) demonstrating continuing activation of YAP1 in this model. 
Protein expression of YAP1 was compared in the control and treated groups (Fig. 
9A). The control and 144 hr Wnt5a treated human neonatal Islet-1+ CPCs were 
analyzed to determine P-YAP protein levels by taking the ratio of P-YAP/YAP1 
protein from each group (Fig. 9B, 9C). At 144 hrs, in the Wnt5a treated group, 
the P-YAP/YAP1 protein levels declined (Fig. 9D). Reduced P-YAP expression 
indicates that YAP1 translocates to the nucleus promoting NRG1 expression 
which is downstream of YAP1 (Fig. 10).  NRG1 can then rebind to the ERBB3 





Figure 8: YAP1 Protein Expression is Elevated in Human Neonatal Islet-1+ 
Cardiac Progenitor Cells at 96 hrs and 144 hrs after Treatment with Wnt5a 
Western blot showing protein expression of YAP1 and actin in Wnt5a treated 
human neonatal Islet-1+ CPCs at 96 hrs and 144 hrs when compared with 
controls (A). YAP1 protein expression at 144 hrs following Wnt5a treatment was 
significantly induced when compared to the control and 96 hr treated group (B). 
Fold changes are shown as the mean + SEM. All samples were run in triplicates 

















Figure 9: P-YAP Protein Expression is Reduced in Wnt5a Treated Human 
Neonatal Islet-1+ CPCs at 144 hrs  
Western blot showing YAP1 protein levels in Wnt5a treated human neonatal 
Islet-1+ CPCs at 144 hrs when compared with controls. (A). P-YAP protein 
expression was compared in the control (B) and Wnt5a treated (C) Islet-1+ CPCs 
at 144 hrs. The relative levels of P-YAP/YAP1 in the 144 hr Wnt5a treated and 

























Figure 10: Decreased P-YAP Expression Promotes Translocation of YAP1 
to the Nucleus  
Diagram showing subsequent increase in intranuclear YAP1 expression (green 
arrow) when P-YAP expression is decreased (red arrow) from 96 hrs to 144 hrs 




























In this study, the ERBB pathway was explored to determine whether 
ERBB signaling participates in cell-based repair following transplantation of 
neonatal sheep Islet-1+ CPCs in a sheep model of myocardial infarction. Using 
sheep as a cell-based repair model can provide new treatment options that can 
be applied to humans in restoring cardiac function and structure after MI. With 
this model, we tested our hypothesis that ERBB activation by NRG stimulates 
YAP1 expression, resulting in upregulation of NRG in an autocrine loop effect. In 
support of this, we showed induction of NRG1, NRG2, ERBB 1-4, and PIK3C2B 
gene expression after neonatal sheep Islet-1+ CPC transplantation in MI sheep. 
We also investigated the hypothesis in human neonatal Islet-1+ CPCs as a clonal 
population and demonstrated that this autocrine loop can be reproduced in vitro 
where NRG1, ERBB3, and PIK3CD gene transcripts were elevated following 
intranuclear translocation of YAP1. The data supports the concept that a 
feedback autocrine loop occurs and is sufficient to maintain YAP1 levels that are 
required for cardiovascular regeneration in this model. NRG1 gene expression 
was not induced solely by infarction, but required the introduction of Islet-1+ cell-
based treatment. Similarly, NRG1 gene expression in infarcted fetal tissue was 
reported to be unchanged when compared to sham tissue after heart injury 
(Lock, 2019). NRG1 activation can stimulate CM proliferation at the site of injury 




of ERBB1, ERBB2, ERBB3, ERBB4, and PIK3C2B in Islet-1+ cell treated 
neonatal sheep when compared to control regions. ERBB gene transcripts signal 
downstream to the PIK3C2B pathway and promote activation of YAP1 
expression by inactivating the Hippo-pathway. Our lab has previously reported 
that YAP1 is induced in Islet-1+ cell treated neonatal sheep (Camberos, 2019). 
Activated YAP1 promotes cardiovascular regeneration. We demonstrate here 
that upregulation of NRG-1 subsequently induces elevated ERBB receptor 
expression which further activates and maintains high levels of YAP1. 
The ERBB pathway has previously been investigated in mice undergoing 
cardiac repair after heart injury. Injection of NRG1 in the cardiovascular zone of 
mice after MI stimulated CMs to transition from a differentiated state to 
proliferative state through the ERBB4/ERBB2 receptors and PI3K pathway 
(Bersell, 2009). It was shown that activation of this signaling pathway leads to 
reduction in infarct size, reduction of CM hypertrophy, and improvement of 
myocardial function in mice after MI (Bersell, 2009). These positive effects were 
also observed when overexpressed ERBB2 was transiently induced in neonatal 
mice after the first week of birth (D’ Uva, 2015). In addition, overexpression of 
ERBB4 in MSCs that were transplanted in MI mice upregulated NRG1, which 
formed a NRG1-ERBB4-NRG1 autocrine loop, promoting CM proliferation and 
dedifferentiation (Liang, 2015). These studies highlight the importance of the 




The Hippo-YAP1 signaling pathway has previously been investigated in 
cardiac studies of neonatal and adult mice.YAP1 expression was reported to be 
robustly detected in neonatal mice, but this expression declines with age (Gise, 
2012). High levels of YAP1 enhance CM proliferation, which is important during 
neonatal cardiac development (Gise, 2012). Conditional inactivation of YAP1 
resulted in the death of neonatal mice due to a decrease in CM proliferation 
(Gise, 2012; Xin 2013). In addition, Yap1 induction post-MI in adult mice 
stimulated CM proliferation, which led to reduced infarct size and improved 
cardiac function (Lin, 2014). Next, the Hippo-Yap1 signaling pathway has 
previously been investigated in porcine models of cardiac repair using RNA 
technology. A study has shown that knockout of the Sav gene by treatment with 
AAV9-Sav–short hairpin RNA (shRNA) post-MI in pigs improved ejection fraction, 
promoted CM division, and reduced scar tissue size in the infarct zone (Liu, 
2021). Furthermore, another study using MicroRNA-199a was shown to stimulate 
cardiac repair in pig hearts following MI by interfering with the Hippo-Yap1 
signaling pathway (Gabsonia, 2019). This interference promoted CMs to return to 
a cell cycle state of proliferation (Gabsonia, 2019). These studies demonstrate 
the importance of YAP1 and its contribution to CM proliferation for cardiac repair. 
In ovarian cancer, ERBB3/ERBB2 activation by NRG1 signals 
downstream to the Hippo-Yap pathway through PI3K in form of an autocrine loop 
(He, 2015; Sheng, 2010). In this model, ERBB3 and NRG1 gene transcripts were 




2015). These findings show that YAP1 can regulate cell proliferation through the 
NRG1-ERBB3 pathway. NRG1 induction deactivates the components of the 
Hippo pathway resulting in activation of YAP by dephosphorylation (He, 2015). 
However, the specific mechanism by which the Hippo pathway switches to 
inactivated state remains unclear. With this in mind, some studies have proposed 
that the Hippo pathway may be connected to the PI3K pathway. Within the PI3K 
pathway, PDK1 was shown to form a complex with the components of the Hippo 
pathway when this pathway is activated (Fan, 2013; Xia, 2018; Zhao, 2018). 
However, this complex dissociates when EGF interacts with EGFR resulting in 
activated PDK1 kinase (Fan, 2013). More specifically, activation of PIK3CA and 
PIK3CB (class 1 PI3Ks) leads to PDK1 activation, which may indirectly inhibit the 
activity of LATS1/2 through some other downstream target within this pathway 
(Zhao, 2018). This shows that PDK1 can act as a regulator of YAP1 activity by 
indirectly targeting the components of the Hippo pathway.  In addition, activated 
YAP1 was shown to be positively regulated by AKT via an indirect mechanism 
(Zhao, 2018). AKT was investigated further to see if it interacts with LATS in the 
Hippo pathway but LATS1 and LATS2 were not affected by co-expression of 
AKT (Zhao, 2018). This data showed that AKT does not affect YAP1 activation 
through the Hippo pathway, but acts directly on YAP1 through an unknown 
mechanism. In our human neonatal Islet-1+ CPC model, we showed a significant 
increase in expression of NRG1, ERBB3, PIK3CD, and YAP1 at 72 hrs. Class 1 




activation of YAP1. We further demonstrated a gradual increase in YAP1 protein 
expression from 96 hrs to 144 hrs in human neonatal Islet-1+ CPCs associated 
with dephosphorylation of YAP1 protein by Western blot. Activation of YAP1 was 
induced and maintained NRG1 expression, allowing NRG1 to rebind to the 
ERBB3 receptor on the cell surface in an autocrine loop effect (Fig.2). 
Conclusion 
Our findings support the involvement of the ERBB3 pathway in cardiovascular 
repair post-infarction via activation of NRG1. Activated ERBB3 relays its signal 
downstream to the PIK3CD pathway (in humans) or PIK3C2B (in sheep) 
stimulating elevated expression of intranuclear YAP1. As a result, NRG1 
becomes upregulated where it participates in an autocrine loop effect with 
ERBB3 receptor on the cell surface. Activation of the NRG1 induced ERBB3 
pathway contributes to cardiomyocyte proliferation, dedifferentiation, growth, and 
survival. Understanding the role of ERBB signaling after cell-based treatment and 
the mechanistic basis by which this pathway interacts with and stimulates YAP1 
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